RxDoctor Payments Data

Maureen Greenwood, NP

Family · Oakland Park, FLNPI 1578759791

Payments from drug & device makers

$9,382in general payments, 2019–2025

Across 228 payments — averaging $41.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$7K
  • Gilead$2K
  • Theratechnologies Inc.$451
  • EMD Serono, Inc.$140
  • Novo Nordisk$94
  • Johnson & Johnson$91
  • plus $212 from 5 others

What the payments were for

  • Consulting fees$3,90042%
  • Travel & lodging$89610%
  • Food & beverage$4,54248%
  • Education$450%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,382 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$5,907
Medicare patients
32
Services billed
109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala663$2,596,737
DescovyEmtricitabine/Tenofov Alafenam235$527,523
TivicayDolutegravir Sodium179$439,795
SerostimSomatropin14$369,302
OdefseyEmtricitab/Rilpiviri/Tenof Ala75$287,764
GenvoyaElviteg/Cob/Emtri/Tenof Alafen63$244,833
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf46$195,510
TrogarzoIbalizumab-Uiyk20$163,006
TriumeqAbacavir/Dolutegravir/Lamivudi41$145,321
IsentressRaltegravir Potassium69$135,140
JulucaDolutegravir/Rilpivirine38$133,525
DovatoDolutegravir Sodium/Lamivudine44$133,503
RukobiaFostemsavir Tromethamine12$97,053
PrezcobixDarunavir/Cobicistat38$96,875
PifeltroDoravirine25$47,697

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya, Truvada$1,504$3,389,468972 claims
Viiv Healthcare CompanyTivicay, Triumeq, Juluca, Dovato, Rukobia$6,890$949,197314 claims
EMD Serono, Inc.Serostim$140$369,30214 claims
MerckIsentress, Pifeltro$59$182,83694 claims
Theratechnologies Inc.Trogarzo$451$163,00620 claims
Johnson & JohnsonPrezcobix$91$96,87538 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in Oakland Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →